Benjamin F. Edwards & Company, Inc. Axogen, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Axogen, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 200 shares of AXGN stock, worth $2,186. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$2,186
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AXGN
# of Institutions
191Shares Held
39.2MCall Options Held
61.7KPut Options Held
42.8K-
First Light Asset Management, LLC Edina, MN4.47MShares$48.9 Million10.62% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$35.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.6MShares$28.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$27.7 Million0.0% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO1.59MShares$17.4 Million0.54% of portfolio
About Axogen, Inc.
- Ticker AXGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 42,283,700
- Market Cap $462M
- Description
- AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...